More From Mike Benson
How Did AstraZeneca’s CVMD Franchise Perform in 2014?
In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.
Major Developments for Eli Lilly and Co. in 4Q15
Eli Lilly and Co.’s (LLY) 4Q15 segment-wise performance was positive for both its Human Pharmaceuticals and Animal Health segments.
Merck & Co.’s Animal Health Segment
The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.
Major Developments for Johnson & Johnson in 3Q16
Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]
Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15
Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.
Analysts’ Ratings and Recommendations for Johnson & Johnson
JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date.
GlaxoSmithKline’s Valuation on June 29
In the first quarter, GlaxoSmithKline reported EPS of 24.60 pence on revenue of 7.2 billion pounds, a 2% fall year-over-year.
How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16?
Johnson & Johnson’s (JNJ) pharmaceuticals segment consists of its immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics franchises.
Pfizer’s Quarterly Revenue Trend in Q2 2018
Pfizer (PFE) reports its revenue into two business segments: Innovative Health and Essential Health.
The Latest Recommendations for Incyte
Wall Street analysts expect Incyte (INCY) to report a 17.8% YoY (year-over-year) rise in sales to $1.81 billion in 2018.
Eli Lilly’s 1Q18 Earnings by Segment
Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health Products.
What Analysts Recommend for Novartis in March 2018
As discussed earlier, Novartis (NVS) reported EPS (earnings per share) of $1.21 on revenues of $12.9 billion during 4Q17.
What Are Sage Therapeutics’ Receptor-Based Products?
Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.
AstraZeneca’s ING Franchise Saw Lower Revenues in 2014
For 2014, AstraZeneca’s ING franchise generated nearly $8.2 billion, a 8.9% decrease as compared to $9.0 billion in 2013.
This Is Eli Lilly’s Animal Health Segment
Eli Lilly’s (LLY) Animal Health segment company, Elanco, reported a 9% YoY fall in revenues at $706 million in 3Q16, as compared to $779 million in 3Q15.
Johnson & Johnson’s 3Q17 Revenue Estimates Could Reveal Growth
Johnson & Johnson’s (JNJ) revenues are expected to report 8.3% growth to $19.3 billion during 3Q17.
A Look at Johnson & Johnson’s Post-2Q17 Valuation
Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.
Lilly’s Total Returns Are Lower than Some Pharma ETFs
The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.
A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.
Johnson & Johnson’s Valuation Cheat Sheet
On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.
Sanofi Increased Net Revenues in 2014
Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.
Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15
Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.
Johnson & Johnson Stock on March 29, 2018
Although Johnson & Johnson stock has fallen ~3.5% in the last month, its stock has risen ~1.4% in the last year.
Analysts’ Estimates and Ratings for Novartis in October
Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
Squire Study Supports Portrazza’s Approval
The FDA approved Portrazza for the treatment of squamous NSCLC based on the results of a phase III study named Squire.
MedMen’s Territory Expansion: The Recent Agreements
MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.
What Analysts Project for Eli Lilly in 3Q17
For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.
Why the Majority of Analysts Deem Novartis a ‘Buy’
Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.
How Analysts View Allergan after Its 1Q18 Earnings
Allergan (AGN) surpassed Wall Street analysts’ estimates, reporting earnings per share of $3.74 on revenues of $3.7 billion during 1Q18.
Johnson & Johnson’s Valuation in February 2018
Johnson & Johnson (JNJ) reported revenues of $20.2 billion in 4Q17, an 11.5% growth compared to 4Q16.
What Does the Future Hold for Seattle Genetics?
Seattle Genetics has surpassed all estimates for earnings per share in the past.
A Look at Allergan’s Valuation on August 16
In this series, we’ll discuss Allergan’s valuation, segment and product performances, recent developments, and analyst recommendations.
Understanding Sanofi’s 3Q17 Performance by Business Segment
Sanofi now reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur (or the Human Vaccines segment).
Analysts’ Recommendations for Merck & Co. after 4Q17
Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.
Bristol-Myers Squibb Continues Revenue Growth in 3Q16
Bristol-Myers Squibb (BMY) reported a growth of 21% to $4.9 billion in its 3Q16 results.
What Does Johnson & Johnson Predict for Its Medical Devices Segment?
Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.
A Closer Look at Pfizer Stock in 1Q18
Pfizer’s stock price has fallen ~3.5% in 1Q18, while its stock price has fallen ~2.9% YTD (year-to-date) as of April 6, 2018.
What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?
Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.
Merck’s Valuation Cheat Sheet for Fiscal 1Q16
Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.
Analysts’ Estimates and Recommendations for Allergan on July 19
Analysts expect Allergan’s second-quarter revenue to fall ~2.5% to $3.9 million compared to its revenue of $4.0 million in the second quarter of 2017.
Allergan’s International Business Segment
Allergan’s International Business segment reported revenue of $864 million during the first quarter.
Pfizer’s 1Q16 Earnings: Products That Saw Sales Drop
The overall share of revenue for Pfizer’s Established Products segment decreased to 44.6% in 1Q16 from 48.8% for 1Q15.
Market Response to EMA Validation of Opdivo Application
BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.
How Did Sanofi’s Merial Segment Perform in 2014?
The contribution of Merial, the animal health arm of Sanofi (SNY), was ~6.0%, or ~2.1 billion euros, towards the company’s total revenues in 2014.
Eli Lilly’s Valuation in December 2017
Eli Lilly (LLY) surpassed analysts’ estimates for EPS and revenues and reported EPS of $1.05 on revenues of $5.7 billion in 3Q17.
Recent Developments for Ionis Pharmaceuticals
On March 6, 2017, Ionis and Akcea announced positive results from the Phase III study APPROACH, evaluating volanesorsen for the treatment of patients with FCS.
Behind Allergan’s US Specialized Therapeutics Segment in 1Q17
In 1Q17, Allergan’s US Specialized Therapeutics segment revenues rose 14.1% to $1.48 billion, as compared to $1.30 billion in 1Q16.
GlaxoSmithKline’s Quarterly Revenue Trend in 4Q17
GlaxoSmithKline (GSK) reported revenues of 7.64 billion pounds in 4Q17, a ~1% growth compared to 7.59 billion pounds in 4Q16.
Pfizer Missed Analysts’ Third-Quarter Revenue Estimates
Pfizer (PFE) released its third-quarter earnings on October 30.
How Does Allergan’s Financial Guidance Look for 2016?
Allergan (AGN) estimates that its revenues will be around $17 billion in 2016.
Johnson & Johnson’s 4Q15 Estimates: Revenues Will Fall
On an annual basis, Johnson & Johnson’s revenues have increased over the past few years following the restructuring of its business segments and strong performance of some of its key products.
Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16
AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.
What’s Driving Pfizer’s Revenue?
Pfizer has divided its product portfolio into two segments: Innovative Health and Essential Health. It reports revenue for both these segments.
Merck Is Getting Serious about Animal Health
Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. The global sales reported for 3Q16 totaled ~$865 million.
Bristol-Myers Squibb’s Profitability and Financial Guidance
Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.
Pfizer’s 1Q16: A Valuation Cheat Sheet
On March 28, 2016, Pfizer was trading at a forward price-to-earnings multiple of ~12.9x.
What Does AstraZeneca’s Growth Platform Offer?
The RI&A (respiratory, inflammation and autoimmunity) segment one of the company’s growth platforms, is a key area of development for AstraZeneca (AZN).
Pfizer’s Key Product Developments in 1Q17
To strengthen the innovative health business, the company is focusing on the development of new drugs as well as expanding the market reach of existing products.
Merck’s Gardasil and What It Could Mean
Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.
Assessing Novartis’s Performance in October So Far
Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.
Analysts Give Mixed Recommendations for Novartis
Novartis’s stock price has fallen ~7.0% in the last 12 months and ~10.7% year-to-date.
A Look Back at Eli Lilly’s 2016 Revenue Trends
Eli Lilly (LLY) reported a ~6% rise in its revenue to $21.2 billion in 2016, compared to its revenue of $20.0 billion in 2015.
What Do Analysts Recommend for Pfizer?
Pfizer reported EPS of $0.67 on revenue of $13.0 billion in 1Q16 against the estimated $0.56 on revenue of $12.1 billion in 1Q16.
How Eli Lilly’s Cardiovascular Franchise Performed in 1Q16
Eli Lilly’s (LLY) cardiovascular franchise contributed ~15.5% of the company’s total revenues in 1Q16.
AstraZeneca’s Other Products in 3Q16
With lower sales from blockbuster drugs Nexium and Seroquel, the contribution of AstraZeneca’s (AZN) Other segment fell to ~21.2% in 3Q16.
Merck’s Gardasil and Other Human Vaccines in 3Q17
Merck & Co.’s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.
Seattle Genetics’ 1Q16 Earnings: What Are Analysts Expecting?
Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.
Merck’s Post-1Q18 Valuation
In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88.
AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.
Expectations from Novartis’s 1Q18 Earnings
Novartis is set to release its 1Q18 earnings on April 19, 2018. Analysts expect it to report earnings per share of $1.28.
WeedMD Secures Cannabis Sales License from Health Canada
On November 13, WeedMD announced that Health Canada approved its cannabis sales license for cannabis cultivated at its greenhouse in Ontario.
Johnson & Johnson’s Revenues Continued to Rise in 1Q18
Johnson & Johnson surpassed Wall Street analysts’ estimates for EPS (or earnings-per-share) and revenues in 1Q18.
Analyzing Merck’s Revenue in 1Q18
Merck (MRK), one of the largest pharmaceutical companies worldwide, reported its 1Q18 results on May 1.
How Merck & Co. Stock Performed in 1Q18
Merck & Co. stock has fallen ~6.4% in 1Q18, while it’s fallen ~5.2% YTD (year-to-date) as of April 6, 2018.
Novartis’s Stock Performance following the AveXis Agreement
Novartis AG (NVS) announced an agreement and plan for a merger with AveXis on April 9, 2018.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
Amgen Stock Rises over 2% on Drug Approvals
Amgen (AMGN) stock has risen ~2.3% in the last week following recent drug approvals.
Decoding Humana’s Revenue Stream in 2015
Humana reported revenues of about $54.3 billion in its 2015 results. This amounts to a 12% revenue growth in 2015, compared to ~$48.1 billion in 2014.
Celgene Stock Performance in 1Q18
Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.
AstraZeneca and Its Oncology Segment’s Growth in 2Q16
AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.
What’s to Be Expected from Novartis’s 3Q16 Earnings?
Novartis, one of the world’s largest pharmaceutical companies by revenue, is set to release its 3Q16 earnings on October 25, 2016.
Johnson & Johnson’s 3Q15 Changes in Growth Rate
Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.
What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?
The price-to-earnings (or PE) multiple represents what one share can buy an equity investor.
How Merck’s Animal Health Segment Did in 1Q18
In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million.
What Drove Ionis’s Revenue in Q1
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.
Ionis Pharmaceuticals’ Valuation on May 23
Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.
What Analysts Think about Ionis
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.
What to Expect from Pfizer’s 2Q16 Earnings
In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.
Allergan’s Business Segments in 1Q18
Allergan’s US Specialized Therapeutics business revenues rose 6.5% to $1.6 billion during 1Q18, compared to $1.5 billion during 1Q17.
How AstraZeneca’s 1Q18 Shook Out
AstraZeneca stock has fallen ~1.2% in 1Q18, and its stock has risen ~2.1% YTD (year-to-date) as of April 6, 2018.
What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
Analysts estimate Bristol-Myers Squibb will post EPS of $0.85 and revenues of $5.2 billion for 1Q18.
Bristol-Myers Squibb’s 2Q16 Estimates: Other Segments
Bristol-Myers Squibb’s (BMY) neuroscience segment is represented by the drug Abilify, while its immuno-science segment is represented by the drug Orencia.
Pfizer Expands Its Investment Portfolio through Pfizer Ventures
On June 6, Pfizer announced that it would invest ~$600 million in biotechnology and emerging growth companies through Pfizer Ventures.
Mylan’s Recent Commercial and Product Developments
Mylan’s recent commercial developments include the acquisition of the Cold-EEZE brand from ProPhase Labs and the acquisition of Meda AB.
What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
GlaxoSmithKline is set to release its 1Q18 earnings on April 25, 2018.
BlueBird Bio Stock Jumps over 6% on May 17
BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.
Novartis’s 1Q16 Earnings Got a Neutral Response from Investors
Novartis (NVS) released its 1Q16 earnings on April 21, 2016. It reported top-line growth of 1% at constant exchange rates for 1Q16—compared to 1Q15.
Allergan Stock Performance in 1Q18
Wall Street analysts estimate that AGN stock has the potential to return 33.7% over the next 12 months.
Merck and AstraZeneca Announced EMA Approval for Lynparza
Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.
Eli Lilly’s Neuroscience Products Sales Dropped in Q2 2018
Zyprexa reported revenues of $128.0 million in Q2 2018, a 9.0% decline in YoY revenues compared to $140.8 million in Q2 2017.